European Nucleic Acid-based Amplification Reagents Markets for Clinical Applications : Market Research Report

European Nucleic Acid-based Amplification Reagents Markets for Clinical Applications

Published: May. 12, 2008 - 75 Pages

1. Executive Summary: 1. Overview
2. Exchange Rates and Glossary of Terms: 1. Glossary and Exchange Rates
3. Industry Challenges and Research Methodology: 1. Research Methodology; 2. Industry Challenges
4. Total European Nucleic Acid-based Amplification Reagents Market for Clinical Applications: 1. Technology Trends; 2. Market Overview for the European Nucleic Acid-based Amplification Reagents Market for Clinical Applications
5. Total Nucleic Acid-based Amplification Reagents Market for Clinical Applications by Geographical Region: 1. Geographical Regions
6. Market Engineering Strategic Recommendations: 1. Strategic Recommendations
7. Database of Key Industry Participants: 1. Key Industry Participants
8. Decision Support Databases: 1. Decision Support Databases for the European Nucleic Acid-based Amplification Reagents Market for Clinical Applications
List of Figures
Chapter 2: Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Exchange Rates (Europe), 2008
Chapter 3: Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Impact of the Top Four Industry Challenges (Europe), 2008-2014
Chapter 4: Total Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Different Amplification Technologies (Europe), 2007; Total Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Market Drivers Ranked in Order of Impact (Europe), 2008-2014; Total Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Revenue Forecasts (Europe), 2004-2014; Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Revenue Forecasts for the Infectious Diseases Segment (Europe), 2004-2014; Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Revenue Forecasts for the Genetic Testing Segment (Europe), 2004-2014; Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Revenue Forecasts for the Transplant Diagnostics Segment (Europe), 2004-2014; Total Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Market Share Analysis (Europe), 2007; Total Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Per cent of Revenues by Geographic Region (Europe), 2007
Chapter 5: Total Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Revenue Forecasts (Germany), 2004-2014; Total Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Revenue Forecasts (Italy), 2004-2014; Total Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Revenue Forecasts (France), 2004-2014; Total Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Revenue Forecasts (United Kingdom), 2004-2014; Total Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Revenue Forecasts (Spain), 2004-2014; Total Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Revenue Forecasts (Benelux), 2004-2014; Total Nucleic Acid-based Amplification Reagents Market for Clinical Applications: Revenue Forecasts (Scandinavia), 2004-2014
Chapter 8: Decision Support Database: Total Population in Million (World), 2002-2012; Decision Support Database: Total Healthcare Expenditure in Billion USD (World), 2002-2012; Decision Support Database: Number of Hospitals (World), 2002-2012; Decision Support Database: Breast Cancer Incidence in '000 (World), 2002-2012; Decision Support Database: Venture Capital Investment in Biotech R & D in Million USD (World), 2002-2012

Abstract

This Frost & Sullivan research service titled European Nucleic Acid-based Amplification Reagents Markets for Clinical Applications provides an overview of market dynamics together with revenue forecasts. It also provides a complete analysis of key market drivers, restraints and trends in the market. Finally, it provides strategic solutions to vendors to gain advantage in this growing market. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: infectious diseases, genetic testing and transplant diagnostics.

European NAT Reagents Market Booming for Clinical Applications

In relation to clinical diagnostics, nucleic acid-based amplification technique (NAT) allows the highly specific detection and quantification of extremely low levels of disease agents. Subsequently, effective therapeutic management through the monitoring of patients can be carried out. One of the major trends in the molecular diagnostics market is the growing number of biomarkers that have been identified, resulting in the surging number of tests that are being commercialised to target these biomarkers. Similarly, the completion of the human genome project is augmenting the number of tests developed for cancer and genetic diagnostics. There are several tests for infectious diseases that use NAT technology, including for HIV, HBV, HCV, HPV, CT, GC, HSV, CMV, MTB, Legionella species, Mycloplasma pneumoniae, Group A strep, EBV and VZV.

Using NAT tests for screening purposes, such as for Human Papilloma Virus (HPV) testing and expanded DTC advertising, augurs well for long-term market growth. The test for HPV screening has already been incorporated in the healthcare system and has proven to be a significant market driver. Similarly, there is an increasing interest in adding tests such as Chlamydia trachomatis and Neisseria gonorrhoeae for screening purposes. Despite reimbursement issues, the sensitivity and the accuracy of NAT technology and the rise in automation are spurring double-digit growth of this segment.

Benefits of NAT Leading to Increased Interest from End-user Base

The results obtained from using NAT techniques instead of immunoassay or culture methods have clearly proven to be more specific and sensitive. For instance, the time taken between infection and the development of antibodies (window period) can cause HIV to be undetectable by ELISA. However, with NAT, the genetic material of the virus is detected directly. "The increase in automation technology and the use of quantitative PCR (qPCR) and multiplexing provides an early, rapid and accurate method to diagnose disease states and medical disorders, supporting reliable treatment regimes," notes the analyst of this research. "End users are slowly realising the benefits of being able to detect clinically relevant genetic variations in patients to help doctors better predict disease risk and progression, and hence select the most appropriate therapy sooner." This can decrease healthcare costs significantly in the long term.

NAT diagnostic kits can play a very important part in detecting infectious agents, genetic disorders, predicting the likelihood of having cancer and monitoring a therapy. However, the major question gripping the industry is whether these technologies are cost effective; the alternative methods for clinical applications such as home-brewed assays, immunoassays, fluorescence in situ hybridisation (FISH) and culture techniques continue to be less expensive than NAT reagents, making reimbursement a critical challenge. "Therefore, strategies such as educating end users and undertaking widespread marketing to make customers aware of NAT products and their benefits can be useful," advises the analyst. "Focusing on automation and multi-parameter kits can encourage the use of this technology, and promote sustained market growth."

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

European Nucleic Acid-based Amplification Reagents Markets for Clinical Applications

Table of Contents

Abstract